



Note: This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

May 8, 2025

Company name: Zeria Pharmaceutical Co., Ltd.
Name of representative: Mitsuhiro Ibe,
Representative Director, President
(Securities code: 4559; Prime Market, TSE)
Inquiries: Koichi Tamura,
Director, Public Relations Division
(Telephone: +81-3-3661-1039)

Notice of Changes in Executive Officers

Zeria Pharmaceutical Co., Ltd. hereby announces that it has decided changes in Executive Officers at the meeting of the Board of Directors held on May 8, 2025.

The changes in Executive Officers will be officially decided at the meeting of the Board of Directors to be held after the 71th Ordinary Stockholders' General Assembly scheduled for June 27, 2025.

1. New candidate of Executive Officer (effective June 27, 2025)

Name	New Position	Current position
Takeshi Watanabe	Executive Officer Director, Central Research Laboratories	Director, Central Research Laboratories

2. Promoting candidate of Executive Officer (effective June 27, 2025)

Name	New Position	Current position
Masakazu Sakurai	Managing Executive Officer Director, European Business Division Licensing	Executive Officer Director, European Business Division Licensing